Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Niccola Funel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5028-2363; OpenAlex author ID A5040728496. Sources: OpenAlex.

Their work

Papers
52 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
151
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 2 papers · 2014: 8 papers · 2015: 6 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 8 papers · 2020: 7 papers · 2021: 4 papers · 2022: 1 paper

Papers 50 of 52

  1. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  2. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  3. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-01892-z↗
  4. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers13164131↗
  5. Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v27.i42.7324↗
  6. Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers. Co-author DOI 10.1007/s13402-020-00548-y↗
  7. Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2020.112088↗
  8. The occurrence of prion protein in surgically resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.004↗
  9. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003084↗
  10. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. Co-author DOI 10.1172/jci.insight.138290↗
  11. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/molecules25020329↗
  12. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. Co-author DOI 10.3748/wjg.v26.i21.2792↗
  13. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  14. A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. Co-author DOI 10.1007/s00464-018-6301-2↗
  15. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  16. New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. Co-author DOI 10.1080/17512433.2019.1693256↗
  17. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Co-author DOI 10.1177/1758835919841233↗
  18. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13508↗
  19. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Co-author DOI 10.2217/pgs-2018-0149↗
  20. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Co-author DOI 10.3390/cancers11050638↗
  21. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  22. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  23. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  24. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  25. Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Co-author DOI 10.1038/srep44686↗
  26. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. Co-author DOI 10.1186/s13045-016-0371-1↗
  27. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  28. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i31.6987↗
  29. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  30. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.ejca.2015.04.006↗
  31. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  32. Pancreatic cancer. Co-author DOI 10.1155/2015/809036↗
  33. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step to… First author DOI 10.1186/s13148-015-0162-5↗
  34. The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors? Co-author DOI 10.2217/epi.15.19↗
  35. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Co-author DOI 10.1038/bjc.2013.681↗
  36. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  37. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Co-author DOI 10.1080/15257770.2014.891741↗
  38. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. Co-author DOI 10.1093/jnci/djt346↗
  39. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0108057↗
  40. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.2104↗
  41. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
  42. Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Co-author DOI 10.4161/21592527.2014.955386↗
  43. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  44. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Co-author DOI 10.2174/138161213804547312↗
  45. Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11095-012-0790-9↗
  46. Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-11-1903↗
  47. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Co-author DOI 10.1158/1535-7163.mct-12-0037↗
  48. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0049145↗
  49. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Co-author DOI 10.1093/annonc/mdq686↗
  50. Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pa… Co-author DOI 10.1159/000322990↗

Closest collaborators

The 25 strongest of 151 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 32 shared papers, 2011–2022 · strength 2.04
  2. Godefridus J. Peters · 16 shared papers, 2011–2020 · strength 0.85
  3. Enrico Vasile · 10 shared papers, 2011–2021 · strength 0.61
  4. Tessa Y. S. Le Large · 7 shared papers, 2014–2021 · strength 0.60
  5. Geert Kazemier M · 6 shared papers, 2016–2021 · strength 0.57
  6. Adam Enver Frampton · 8 shared papers, 2013–2022 · strength 0.55
  7. Luca Morelli · 5 shared papers, 2020–2021 · strength 0.52
  8. Amir Avan · 11 shared papers, 2012–2019 · strength 0.50
  9. Btissame El Hassouni · 5 shared papers, 2019–2021 · strength 0.48
  10. Ugo Boggi · 12 shared papers, 2011–2019 · strength 0.46
  11. Gregorio Di Franco · 4 shared papers, 2020–2021 · strength 0.41
  12. Connie R. Jiménez · 4 shared papers, 2019–2021 · strength 0.39
  13. Maarten F. Bijlsma · 4 shared papers, 2019–2021 · strength 0.39
  14. Caterina Vivaldi · 3 shared papers, 2019–2021 · strength 0.30
  15. Matteo Bianchini · 3 shared papers, 2020–2021 · strength 0.30
  16. Mina Maftouh · 7 shared papers, 2013–2017 · strength 0.29
  17. Hanneke W.M. van Laarhoven · 3 shared papers, 2019–2021 · strength 0.29
  18. Laura L. Meijer · 3 shared papers, 2016–2020 · strength 0.27
  19. Daniela Campani · 7 shared papers, 2011–2019 · strength 0.26
  20. Claudio Ricci · 3 shared papers, 2014–2021 · strength 0.25
  21. Mjriam Capula · 2 shared papers, 2019–2020 · strength 0.24
  22. Leandro Castellano · 4 shared papers, 2014–2019 · strength 0.23
  23. Ingrid Garajová · 3 shared papers, 2015–2020 · strength 0.22
  24. Vittoria Raffa · 2 shared papers, 2020–2021 · strength 0.21
  25. Alice Usai · 2 shared papers, 2020–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.